Exane Derivatives Purchases 2,249 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Exane Derivatives boosted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating) by 7,496.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,279 shares of the company’s stock after acquiring an additional 2,249 shares during the quarter. Exane Derivatives’ holdings in Axsome Therapeutics were worth $87,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Captrust Financial Advisors increased its stake in Axsome Therapeutics by 582.0% in the first quarter. Captrust Financial Advisors now owns 757 shares of the company’s stock valued at $31,000 after acquiring an additional 646 shares during the last quarter. Atticus Wealth Management LLC increased its stake in Axsome Therapeutics by 33.3% in the first quarter. Atticus Wealth Management LLC now owns 1,200 shares of the company’s stock valued at $50,000 after acquiring an additional 300 shares during the last quarter. Clearstead Advisors LLC increased its stake in Axsome Therapeutics by 28.6% in the first quarter. Clearstead Advisors LLC now owns 1,350 shares of the company’s stock valued at $56,000 after acquiring an additional 300 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Axsome Therapeutics in the first quarter valued at approximately $141,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Axsome Therapeutics by 27.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,827 shares of the company’s stock valued at $158,000 after acquiring an additional 831 shares during the last quarter. 54.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AXSM shares. Cowen lifted their price objective on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday, June 29th. Cowen boosted their target price on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 29th. Mizuho boosted their target price on shares of Axsome Therapeutics from $49.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, September 7th. Cantor Fitzgerald decreased their target price on shares of Axsome Therapeutics from $64.00 to $54.00 in a research note on Wednesday, August 10th. Finally, Truist Financial boosted their target price on shares of Axsome Therapeutics from $100.00 to $150.00 in a research note on Friday, August 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $108.56.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $58.13 on Wednesday. The firm has a market cap of $2.26 billion, a PE ratio of -14.83 and a beta of 1.68. The firm’s fifty day moving average is $51.57 and its 200-day moving average is $39.44. The company has a debt-to-equity ratio of 6.15, a quick ratio of 2.20 and a current ratio of 2.44. Axsome Therapeutics, Inc. has a 52 week low of $20.63 and a 52 week high of $71.98.

Axsome Therapeutics (NASDAQ:AXSMGet Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($1.06) EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.13. The business had revenue of $8.82 million for the quarter, compared to analyst estimates of $9.59 million. During the same quarter last year, the firm posted ($0.86) EPS. Sell-side analysts predict that Axsome Therapeutics, Inc. will post -4.31 earnings per share for the current year.

About Axsome Therapeutics

(Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

See Also

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.